Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Camurati-Engelmann Syndrome 1Advanced Solid Tumors 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × ascrinvacumab × Clear all
NCT05178043 2024-02-22

GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Suzhou Kintor Pharmaceutical Inc,

Phase 2 Unknown
5 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01337050 2015-10-28

Asian Phase I Study Of PF-03446962

Pfizer

Phase 1 Completed
36 enrolled 24 charts
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT01911273 2015-10-28

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

Pfizer

Phase 2 Terminated
3 enrolled 4 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡